Abstract

Allergy is a global issue, however, medical intervention for allergy treatment is limited. Recent studies have focussed on allergy prevention with food factors. In this study, Lactobacillus plantarum 22 A-3 (LP22A3) exerted an anti-allergic effect in passive cutaneous anaphylaxis (PCA) reaction and increased transforming growth factor (TGF)-β contents in blood. The increase of TGF-β contents in blood by exogenous TGF-β injection intraperitoneally decreased Evans blue release into mice ears to the same level as LP22A3 treatment in PCA reaction. LP22A3 treatment directly to RBL-2H3 cells shows no effect on β-hexosaminidase release from RBL-2H3 but inhibited its release using the Caco-2/RBL-2H3 cells co-culture system stimulated with LP22A3 from the apical side. Moreover, TGF-β treatment to RBL-2H3 inhibited β-hexosaminidase release from RBL-2H3. However, β-hexosaminidase release was cancelled by TGF-β neutralising antibody without the influence of TGF-β mRNA expression in Caco-2 cells. These results showed that LP22A3 ameliorates allergy by TGF-β secretion through the intestine.

摘要

过敏是一个全球性问题，然而，过敏治疗的医疗干预是有限的。最近的研究集中于食物因素的过敏预防。在本研究中，植物乳杆菌22 A-3 (LP22A3) 在被动皮肤过敏 (PCA) 反应中发挥抗过敏作用，并增加血液中的转化生长因子 (TGF) -β 含量。通过腹腔注射外源性 TGF-β 增加血液中 TGF-β 的含量，将伊文思蓝释放到小鼠耳中，使其与 PCA 反应中 LP22A3 处理的水平相同。LP22A3 对 RBL-2H3 细胞的直接处理对 RBL-2H3 的 β-氨基己糖苷酶释放没有影响，但使用 Caco-2/RBL-2H3 细胞共培养系统从顶端用 LP22A3 刺激，抑制了其释放。此外，TGF-β 对 RBL-2H3 的处理抑制了 β-氨基己糖苷酶从 RBL-2H3 中释放。然而，β-氨基己糖苷酶的释放被 TGF-β 中和抗体取消，而不受 Caco-2 细胞中 TGF-β mRNA 表达的影响。